A new collaborative drug discovery project in Friedreich’s Ataxia (FA) between the University of Oxford, Ataxia UK, Pfizer Inc, UCL and Imperial College London was recently announced.
The collaboration was initiated by Ataxia UK, the national charity for people living with ataxia. It brings together academic researchers who will work together with Pfizer scientists based both in the US (Cambridge MA) and at Pfizer’s new Genetic Medicine Institute in London.
Friedreich’s ataxia is an inherited, progressive disorder that affects co-ordination, balance and speech  with patients typically left unable to walk around 15 years after diagnosis.
Dr Michele Lufino, the University of Oxford researcher leading the collaboration commented: “Finding therapies for Friedreich’s Ataxia is a challenging undertaking which requires a radically novel research approach. At Oxford we believe that collaboration is key to succeed in this complex task and for this reason we are particularly proud of the collaboration that Ataxia UK has helped establish by bringing together leading researchers from industry and academia.”
The programme will initially run for three years and aims to develop a potential new medicine or therapy for Friedreich’s ataxia that, if successful, may be tested in clinical trials. The following academic researchers will conduct the investigations:
- Dr Michele Lufino, from the Department of Physiology, Anatomy and Genetics at the University of Oxford, who has developed methods to study the effect of drugs in cell and animal models of FA and to better understand the FA mechanism of disease.
- Dr Paola Giunti from University College London, who brings her basic research studies on the functionality of the frataxin protein in cell and animal models and clinical expertise from running the London Ataxia Centre.
- Professor Richard Festenstein from Imperial College, London, who has expertise on the frataxin gene regulation and has recently completed a clinical trial of nicotinamide in FA patients with Dr Giunti.
- “The research model created with the help of Ataxia UK brings an increased patient focus to our efforts. I’m excited by the potential of bringing together the collective wisdom of three of the UK’s top ataxia researchers from three of the world’s finest universities. Collaborative models like this represent the future for rare diseases research, where everyone pools resources with a common purpose of trying to accelerate medicine discovery in an area of significant unmet need,” says Michael Skynner, Head of the Pfizer Rare Disease Consortium.This collaboration signifies another positive step forward towards strengthening research partnerships for the purpose of accelerating drug discovery within the rare disease community.